|Day Low/High||108.91 / 112.87|
|52 Wk Low/High||92.56 / 141.86|
Charts of the Boston-based biotech to do not provide a compelling case to buy the stock.
Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
The two are homebuilding and biotech, and there are stocks within those sectors where I've parked my money.
The SPDR S&P Biotech ETF, Alexion Pharmaceuticals and BioMarin Pharmaceuticals set up nicely for this options strategy.
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
The names include a veterinary drug concern plus companies with successful drugs on the market.
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
It has been a better year for the Russell 2000 and the small-caps it represents.
The market's day-to-day extreme volatility tested even the most seasoned investors. Adhering to portfolio principles can help.
Straying from these names could land you in quicksand as the 4th quarter begins.
Big-cap FAANG names and Apple, in particular, were the beneficiaries.
I think M&A activity will pick up markedly going forward across the industry.
A look at three names to consider in the biotech and biopharma space.
Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.
These favorite names in the volatile sector offer the potential for high rewards.
The Cambridge, Mass.-based firm unveiled positive top-line results from its Phase 2 study of SAGE-217 in patients with moderate to severe major depressive disorder.
Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.
There are a variety of players that should be active in the M&A space next year.
The path of least resistance is downward for Alexion.
The New Haven, Conn.-based firm said Monday it has secured approval from the U.S. Food and Drug Administration for Soliris (eculizumab) as a treatment for adults with generalized myasthenia gravis (gMG) that are anti-acetylcholine receptor (AChR) antibody-positive.